Aurobindo Pharma Limited (NSE:AUROPHARMA)

Revenue by Segment

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
Pharmaceutical Products	336.53B	317.24B	290.02B	248.55B	234.55B
Total	336.53B	317.24B	290.02B	248.55B	234.55B

Revenue by Geography

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
India	33.27B	36.01B	34.02B	27.48B	26.70B
USA	143.59B	144.78B	139.80B	112.42B	105.21B
Europe	106.88B	92.36B	75.63B	72.43B	78.81B
Rest of the World	52.78B	44.08B	40.56B	36.22B	23.83B
Total	336.53B	317.24B	290.02B	248.55B	234.56B

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 21, 2026

Data Sources Report a data error